Alnylam Pharmaceuticals Stock Current Valuation
| ALNY Stock | USD 271.31 5.85 2.11% |
Valuation analysis of Alnylam Pharmaceuticals helps investors to measure Alnylam Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is likely to rise to -109.06 in 2025. Enterprise Value Multiple is likely to rise to -109.06 in 2025. Fundamental drivers impacting Alnylam Pharmaceuticals' valuation include:
Fairly Valued
Today
Please note that Alnylam Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Alnylam Pharmaceuticals is based on 3 months time horizon. Increasing Alnylam Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Alnylam Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Alnylam Stock. However, Alnylam Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 271.31 | Real 263.68 | Target 298.97 | Hype 271.31 | Naive 274.81 |
The intrinsic value of Alnylam Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Alnylam Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Alnylam Pharmaceuticals helps investors to forecast how Alnylam stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Alnylam Pharmaceuticals more accurately as focusing exclusively on Alnylam Pharmaceuticals' fundamentals will not take into account other important factors: Alnylam Pharmaceuticals Company Current Valuation Analysis
Alnylam Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Alnylam Pharmaceuticals Current Valuation | 33.52 B |
Most of Alnylam Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Alnylam Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Alnylam Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Alnylam Pharmaceuticals is extremely important. It helps to project a fair market value of Alnylam Stock properly, considering its historical fundamentals such as Current Valuation. Since Alnylam Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Alnylam Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Alnylam Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Alnylam Pharmaceuticals has a Current Valuation of 33.52 B. This is 133.34% higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is 101.61% lower than that of the firm.
Alnylam Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alnylam Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Alnylam Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Alnylam Pharmaceuticals by comparing valuation metrics of similar companies.Alnylam Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Alnylam Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Alnylam Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Alnylam Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Alnylam Fundamentals
| Return On Equity | -15.01 | ||||
| Return On Asset | -0.0292 | ||||
| Profit Margin | (0.16) % | ||||
| Operating Margin | (0.15) % | ||||
| Current Valuation | 33.52 B | ||||
| Shares Outstanding | 128.98 M | ||||
| Shares Owned By Insiders | 0.42 % | ||||
| Shares Owned By Institutions | 98.15 % | ||||
| Number Of Shares Shorted | 3.15 M | ||||
| Price To Earning | (22.92) X | ||||
| Price To Book | 1,082 X | ||||
| Price To Sales | 16.71 X | ||||
| Revenue | 1.83 B | ||||
| Gross Profit | 1.79 B | ||||
| EBITDA | (258.24 M) | ||||
| Net Income | (440.24 M) | ||||
| Cash And Equivalents | 2.27 B | ||||
| Cash Per Share | 18.41 X | ||||
| Total Debt | 2.68 B | ||||
| Debt To Equity | 5.63 % | ||||
| Current Ratio | 3.48 X | ||||
| Book Value Per Share | 0.25 X | ||||
| Cash Flow From Operations | 104.16 M | ||||
| Short Ratio | 4.82 X | ||||
| Earnings Per Share | (2.63) X | ||||
| Price To Earnings To Growth | (0.49) X | ||||
| Target Price | 299.74 | ||||
| Number Of Employees | 2.1 K | ||||
| Beta | 0.39 | ||||
| Market Capitalization | 34.99 B | ||||
| Total Asset | 3.83 B | ||||
| Retained Earnings | (7.01 B) | ||||
| Working Capital | 2.01 B | ||||
| Current Asset | 1.11 B | ||||
| Current Liabilities | 62.1 M | ||||
| Net Asset | 3.83 B |
About Alnylam Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alnylam Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alnylam Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alnylam Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Alnylam Stock Analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.